asa guidelines for glp-1 The 2023 position on receptor agonists has been overturned by three 2025 consensus statements. Continue the drug. Change the fast. ANZCA/ADS/GESA/NACOS, the Association of Anaesthetists/RCoA, and SPAQI/AACE now converge on Perioperative Management of GLP-1 Receptor

Dermatologic monitoring remains mandatory in the EU treatment program

GLP-1 medications can cause profound appetite suppression an effect that, for someone with restrictive eating, can reinforce dangerous patterns of food restriction, reduce food intake to medically dangerous levels, and provide what feels like medical sanction for not eating

Hydroxyzine Addiction: Exploring the Hidden Risks Personalized Programs Designed to Fit Your Recovery Needs

Our clients cant stop raving about their CoolSculpting experiences

A note on how the two names are used in this article To keep the evidence honest, this review uses BPC-157 for the pentadecapeptide throughout, because the studied molecule and the named molecule are the same